The genes erm(B), mef(A), and both erm(B) and mef(A) were identified in 42.6, 10.1, and 47.3%, respectively, of the erythromycin-resistant Streptococcus pneumoniae isolates. Of the strains, 3.8% were nonsusceptible to levofloxacin and had 1 to 6 amino acid changes in the quinolone resistance-determining region, including a new mutation, Asn94Ser, in the product of parC. Levofloxacin with reserpine was highly specific for efflux screening.
The increase in the resistance of Streptococcus pneumoniae to primary antibiotic agents has become a serious problem (1) . Previous reports documented high rates of penicillin and erythromycin resistance among clinical isolates from Asia with the spread of the Taiwan19F and the Spain23F clones (19) . Fluoroquinolones are now recommended for the empirical treatment of S. pneumoniae infection (9) . Although increasing rates of resistance have been described in a few previous reports, the rate of fluoroquinolone resistance among S. pneumoniae isolates remains low worldwide (4, 7, 14, 15, 17) . We describe the antimicrobial susceptibility of S. pneumoniae to commonly used antimicrobial agents and focus on the prevalence of genotypes and the molecular epidemiology of macrolide and fluoroquinolone resistance among isolates of S. pneumoniae from five tertiary-care hospitals in Korea.
A total of 235 isolates of S. pneumoniae were collected from five tertiary-care hospitals between 2002 and 2006. The organisms were isolated from the lower respiratory tract (68.5%), blood (14.9%), the upper respiratory tract (6.8%), the ear (3.4%), pus (2.6%), the eye (1.7%), and other sites (2.1%). Antimicrobial susceptibility testing was performed using the broth microdilution method, and results were interpreted according to the guidelines of the Clinical and Laboratory Standards Institute (CLSI) (5, 6) . The S. pneumoniae ATCC 49619 strain was used as a control. The bacterial genomic DNA was prepared with a genomic DNA preparation kit (Solgent Co., Daejeon, Korea). The PCRs for macrolide resistance genes and mutations in the quinolone resistance-determining region (QRDR) were performed with the primers listed in Table 1 . The purified DNA was sequenced with the ABI PRISM 3130xl genetic analyzer (Applied Biosystems, Foster City, CA). The efflux phenotype was inferred from a fourfold or greater reduction in the MICs of any of the three fluoroquinolones (norfloxacin, ciprofloxacin, and levofloxacin) tested in the presence of reserpine (10 g/ml; Sigma, St. Louis, MO). A reverse transcriptase PCR was performed to detect pmrA expression (12) . Multilocus sequence typing and serotyping by Pneumotest-Latex (Statens Serum Institut, Copenhagen, Denmark) were conducted with nine levofloxacin-nonsusceptible isolates to assess clonality.
Antimicrobial susceptibility results. The rate of resistance to penicillin was 67.2%. The highest rates of resistance were those to erythromycin (80%) and tetracycline (81.3%) ( Table  2 ). Nine strains (3.8%) were nonsusceptible to levofloxacin, with seven resistant and two intermediate, and 185 isolates (78.7%) were multidrug resistant. 
Distribution of macrolide resistance genes and QRDR mutations. The genes erm(B), mef(A), and both erm(B)
and mef(A) were identified in 42.6, 10.1, and 47.3% of the erythromycin-resistant isolates. No erm(TR)-positive isolates were detected. Levofloxacin-nonsusceptible strains had 1 to 6 amino acid changes in the QRDRs, including a new mutation, Asn94Ser, in the product of parC ( Table 3 ). All of the levofloxacin-nonsusceptible strains contained an Ile460Val alteration in the product of parE. Three isolates possessed only 1 amino acid substitution within the product of parE. The clonal profile in general was heterogeneous, although a few isolates may have a clonal relation.
Reserpine efflux screening and pmrA expression. Among the 235 isolates, 177 showed an efflux phenotype (norfloxacin, n ϭ 134 [57.0%]; ciprofloxacin, n ϭ 109 [46.4%]; and levofloxacin, n ϭ 7 [3.0%]). Among nine levofloxacin-nonsusceptible isolates, an efflux phenotype corresponding to norfloxacin, ciprofloxacin, and levofloxacin was detected in three, six, and five strains, respectively. Only 2 of 226 levofloxacin-susceptible isolates exhibited the efflux phenotype when levofloxacin was used with reserpine (MIC, 2 g/ml). All three isolates showing only a parE mutation had an efflux phenotype. Among the isolates showing an efflux phenotype, 85.4% expressed the pmrA gene.
These study results indicate high rates of resistance of S.
pneumoniae to many antimicrobial agents and an uncommon increase in levofloxacin resistance in Korea. We ascertained that the presence of both erm(B) and mef(A) was highly related to multidrug resistance, as Brown et al. reported previously (3). All levofloxacin-nonsusceptible isolates had an Ile460Val alteration in the product of parE, with three isolates showing this change as the only substitution. This finding differs from results in previous reports. The high prevalence of a single Ile460Val mutation in the parE product was also described in a previous report (18) , but the authors of that study reported that all except 1 of 78 isolates with a single parE mutation were susceptible to levofloxacin. We presume that the high-level levofloxacin resistance of isolates with parE-only mutations was associated with efflux pump mechanisms (see below). The numerous QRDR mutations may not have any major effect on the fluoroquinolone MICs, as noted in a previous report (3) . It is considered that for S. pneumoniae, ciprofloxacin is the drug most susceptible to efflux mechanisms (2, 7, 13, 21) . In this study, efflux mechanisms were also found more commonly when efflux screening was performed with norfloxacin or ciprofloxacin than when levofloxacin was used. However, for the fluoroquinolone-nonsusceptible isolates, levofloxacin was superior to norfloxacin and similar to ciprofloxacin in detecting 
